BTIG raised the firm’s price target on Glaukos (GKOS) to $118 from $117 and keeps a Buy rating on the shares. The company’s iDose sales were “just above” Buy-side expectations and its second-half of 2025 is anticipated to face some headwinds, though the management commentary on growing MAC coverage and adoption should be viewed favorably by longs, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GKOS:
- Glaukos price target lowered to $130 from $150 at Mizuho
- Glaukos’s iDose Success and Promising Growth Potential Drive Buy Rating
- Glaukos Corporation Reports Strong Q2 2025 Growth
- Closing Bell Movers: Microsoft jumps 9%, Meta up 12% on earnings beats
- Glaukos Reports Record Q2 Sales, Raises 2025 Guidance